Japanese pharmaceutical company
The acquisition by Astellas of Audentes, which researches and develops treatments for serious neuromuscular diseases, is expected to be completed in the first quarter of 2020. The Japanese firm eventually aims to acquire full shares of the
"By joining together with Audentes' talented team, we are establishing a leading position in the field of gene therapy with the goal of addressing the unmet needs of patients living with serious, rare diseases,"
"With its focus on innovative science and a global network of research, development and commercialization resources, we believe that operating as part of the Astellas organization optimally positions us to advance our pipeline programs and serve our patients," said Audentes Chairman and CEO
Audentes was founded in 2012 and is currently listed on the
==Kyodo
© Kyodo News International, Inc., source